脑室内联合静脉替加环素治疗婴儿脑室腹腔分流管感染中达托霉素不敏感万古霉素耐药肠球菌
本文报道一例婴儿脑室腹腔分流管感染,病原为达托霉素不敏感的万古霉素耐药屎肠球菌,采用脑室内联合静脉替加环素治疗并获得成功。作者称这是据其所知首例以该方案成功治疗达托霉素耐药VRE屎肠球菌所致VP分流管感染的报告,并指出替加环素尚未获批用于儿童、剂量与副作用数据不足。
要点
- VP分流管感染发生率为4%-17%,最常见病原为表皮葡萄球菌
- 达托霉素耐药肠球菌全球监测数据<1.0%
- 替加环素在儿童中尚未获批,剂量与副作用数据不足
核心结论
- 脑室内联合静脉使用替加环素是治疗达托霉素耐药VRE屎肠球菌所致VP分流管感染的一种挽救生命的选项。
- 替加环素尚未获批用于儿童,相关剂量与副作用数据不足。
研究设计与样本
- 个案报道:一例婴儿VP分流管感染,病原为达托霉素不敏感的万古霉素耐药屎肠球菌(VRE faecium),采用脑室内联合静脉替加环素治疗。
主要发现
- 该例为据作者所知首例以脑室内联合静脉替加环素成功治疗达托霉素耐药VRE屎肠球菌所致VP分流管感染的报告。
- VP分流管感染发生率为4%-17%,最常见致病菌为表皮葡萄球菌。
- 全球监测数据显示肠球菌对达托霉素耐药率<1.0%。
关键数值与推荐
- VRE中枢神经系统感染罕见;对VRE有活性的药物包括达托霉素、利奈唑胺、喹奴普汀/达福普汀和替加环素。
- VP分流管感染发生率为4%-17%。
- 肠球菌达托霉素耐药率<1.0%(全球监测数据)。
临床怎么用
- 对达托霉素不敏感VRE所致VP分流管感染,在缺乏儿童获批药物的情况下,脑室内联合静脉替加环素可作为挽救性治疗选择。
- 儿童使用替加环素需注意其尚未获批、剂量与副作用数据不足的问题。
局限性
- 单个病例报告,证据级别有限。
- 替加环素在儿童中的剂量与副作用数据不足,且尚未获批用于儿童。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ventriculoperitoneal (VP) shunt infection, which is 1 of the most important complications of VP shunt is observed at a rate of 4%-17%. Staphylococcus epidermidis is the most common causative agent. Vancomycin-resistant Enterococcus (VRE) is an increasingly common nosocomial pathogen that rarely causes central nervous system infections globally. Current treatment options that have shown appreciable activity against various VRE infections include daptomycin, linezolid, inquinupristin/dalfopristin, and tigecycline. Daptomycin has a particular mode of action and a potent bactericidal activity, making it a useful addition to the clinician's antibiotic collection. Global surveillance data indicate <1.0% rates of daptomycin resistance in enterococci. CASE DESCRIPTION: Here, we describe, to the best of our knowledge, the first case of successful intraventricular plus intravenous use of tigecycline to treat VP shunt infections caused by daptomycin resistant VRE faecium. CONCLUSION: Tigecycline is a life-saving option in the treatment of resistant nosocomial infections but it has not yet been approved for use and there are not enough data in terms of dose and side effects associated with its use in children.
引用
- Şahin A, Dalgic N. Intraventricular Plus Intravenous Tigecycline for the Treatment of Daptomycin Nonsusceptible Vancomycin-Resistant Enterococci in an Infant with Ventriculoperitoneal Shunt Infection. World Neurosurg. 2019. PMID: 31302272. doi:10.1016/j.wneu.2019.07.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。